Exporting unspliced human immunodeficiency virus type 1 function, thereby inhibiting viral replication. In the present (HIV-1) RNA from the nucleus to the cytoplasm, through studies, different HIV-1 RRE region-specific hammerhead an interaction between the viral regulatory Rev protein and ribozymes were constructed and their anti-HIV-1 repliRev response element (RRE) RNA, is a critical step in the cation effects were assayed in diverse RNA polymerase HIV-1 life-cycle. Disruption of either Rev or the RRE will (pol) II and III promoters and vector systems in cell culture. completely inhibit HIV-1 replication. As such, a strategy for Utilizing this combination of an SFv and a ribozyme as a somatic gene therapy to treat HIV-1 infection by intracelludual strategy to block HIV-1 replication, both at the protein lar expression of an anti-HIV-1 Rev single chain variable and RNA level, data from these studies demonstrated that fragment (SFv) and a ribozyme which specifically targets potent inhibition of HIV-1 replication can be achieved via the RRE was developed. The anti-Rev D8SFv, which this approach. Combination gene therapies hold promise, specifically targets the Rev activation domain, may be a analogous to combination chemotherapeutic regimens, for key component of combination intracellular immunization, the in vivo treatment of HIV-1 infections. as it has been previously shown to potently inhibit Rev
Introduction
reverse transcriptase (RT), integrase, Tat, Nef and Integrated into the host cell's genome, the HIV-1 provirus gp120. [6] [7] [8] [9] Via inhibition of different viral targets, the HIVappears to function as a series of genes and genetic 1 life-cycle can now be specifically inhibited at pre-or elements within HIV-1-infected patients. As such, the post-integration stages in cell culture. This protein-based acquired immune deficiency syndrome (AIDS) has simiintracellular immunization strategy not only shows a larities to an acquired genetic disease. HIV-1-infected high potency in inhibiting HIV-1 replication, but also cells can be divided into three general categories: those demonstrates the specificity of the single chain variable with active viral production and high cellular turnover, fragment (SFv)-based approach. [6] [7] [8] [9] productive viral replication from long-lasting cells (eg Hammerhead ribozymes are RNA motifs capable of certain macrophage populations) and latently infected the magnesium-dependent, site-specific cleavage of RNA cells. With at least nine open read frames (orf), and are utilized by a number of small pathogenic plant uses several strategies to control its replication and virions and satellite RNAs for processing during rollingescape host immune responses, with a high rate of cycle replication. 10 The hammerhead ribozyme motif mutagenesis. [1] [2] [3] In the past, several strategies have been cleaves the phosphodiester bond downstream of a GUX developed for intracellularly expressing anti-HIV-1 moitriplet, where X can be C, U or A. GUC is the triplet that eties, such as the antisense approaches, ribozymes, viral is most efficiently cleaved. Target specificity for this dominant-negative mutant proteins or multimers of the cleavage can be achieved by flanking the hammerhead Tat activation region (TAR) and the Rev response ribozyme motif with antisense sequences, complemenelement (RRE) for inhibition of viral replication. 4, 5 It is tary to the target RNA. 11 Recently, ribozymes have been apparent that to target the viruses' highly conserved targeted to a wide variety of substrates and tested in biofunctional protein domains or viral RNA structures for logical systems, to achieve inhibition of cellular gene inhibition of viral replication may require prevention of expression or viral replication. 12 escape mutations, as a key element for long-term theraWith viral RNA as the packaged genetic material, peutic benefit of HIV-1-infected patients. 4 using RT as a virion-encapsidated functional enzyme, Recently, in order to specifically inhibit HIV-1, we have HIV-1 shows a high mutation rate and easily generates developed several panels of protein-based anti-HIV-1 escape mutants from several chemotherapeutic treatmoieties, which are derived from modified murine and ments. 3 Although we have developed strategies for SFvs to target highly conserved HIV-1 protein functional domains, to prevent escape mutations a dual-blocking strategy of targeting other HIV-1 proteins or targeting extremely useful. For testing this dual-blocking strategy, two HIV-1 RRE-specific hammerhead ribozymes have been generated. Due to the complexity of intracellular ribozyme function, our laboratories have set up several systems for functional analysis of the intracellular efficiency of RRE-specific ribozymes. Then, a combination construct of a functional ribozyme, with an anti-HIV-1 Rev SFv, was created. The data presented in this report indicate that it is possible to functionally combine the protein-and RNA-based HIV-1 inhibition strategies, in single constructs.
Results
Development and design of RRE-specific ribozymes One of the parameters which determine intracellular ribozyme function is the molecular ratio of target RNA (substrate) and ribozyme RNA. Intracellular ribozyme RNA expression levels can be manipulated by either increasing RNA transcription, such as by using RNA polymerase (pol) III promoters, 13 fusing ribozyme RNA with an rRNA transcription unit, 14 or modifying the structure of the expressed ribozymes to increase stability. 15 Of note, for inhibition of HIV-1, full-length unspliced viral RNA should be an ideal target for a combination anti-Rev SFv/ribozyme dual-blocking strategy.
The HIV-1 Rev regulatory protein functions not only in unspliced viral RNA translocation from the cell nucleus to the cytoplasm, but also binds to the RRE region to stabilize viral RNA. Without functional Rev, the full-length viral RNA is reduced to nearly undetectable levels. 16 The low-level of unspliced viral RNA may be important for ribozyme-based RNA target strategies. In the case of intracellular expression of anti-Rev SFv, the 
V catalytic domain (b).
The parameters which are involved in intracellular cleavage of target RNA by specific ribozymes are not fully understood. 18 In order to search for the best cleavin the presence of Mg +2 . When these ribozymes were age site for an anti-RRE ribozyme, all of the GUC triplets incubated with the substrate RNA at a 1:1 molar ratio for in the HIV-1 IIIB and NL4-3 strains' RRE region 20 min, the substrate RRE RNA was cleaved, at the sequences were analyzed by using a computer-assisted expected specific sites, into P1 and P2 fragments. Data in program, which predicts the secondary structure of RNA Figure 2 demonstrate that ribozymes (II and V) cleave the molecules.
19 Figure 1 illustrates the two sequences of the target RRE RNA at specific sites in a cell-free cleavage trans-acting hammerhead ribozymes, designed to cleave system, equally well. By combining the two transcribed the selected GUC triplets in RRE RNA sequences near ribozymes (II and V) in a single construct, more efficient the loop structures, which were finally selected for testing in vitro cleavage of the targeted RRE RNA was obtained in the present studies (ribo-II and V). A mutant ribozyme (see Figure 2) . Utilizing phosphorimager analysis with a two base alteration in its functional domain is also (Molecular Dynamics, Sunnyvale, CA, USA), this combiillustrated in Figure 1 (ribo-Vm). Of importance, this tarnation of ribozymes was demonstrated to be additive get region in the RRE is well-conserved among different (cleavage efficiency: ribozymes II, 46%; V, 57%; and II clades of HIV-1. 36 and V, 82%).
Inhibition of HIV-1 replication in T lymphocytic cells
In vitro ribozyme-mediated cleavage of HIV-1 RRE RNA Construction and cloning of ribozymes-II, V, II+V, the transduced with retroviral vectors expressing ribozymes driven by a pol III promoter HIV-1 RRE sequence for the substrate in ribozyme cleavage assays, and in vitro transcription and purification of In our recent ribozyme-mediated ␣1-antitrypsin gene replacement studies, we have found that a hammerheadthe substrate and ribozymes, are described in the Materials and methods. In vitro transcribed hammerhead structure ribozyme, similar to the anti-HIV-1 RRE ribozymes, functions much more efficiently when ribozymes, ribo-II (118 bases) and ribo-V (124 bases), were incubated with a 274 base substrate of RRE RNA expressed from a pol III promoter, as compared to a pol bition of HIV-1 replication in retrovirus-transduced, mixed SupT1 cell populations, in multiple independent experiments (Figure 4a ). This inhibition of viral repli-II promoter. 20 To study the effect of anti-RRE ribozymes on the inhibition of HIV-1 replication in human T lymcation was solely due to ribozyme function, not antisense effects, as the ribozyme-Vm construct, with two mutated phocytic cells, SupT1 cells, which can be infected with HIV-1 and support high-level viral replication, 6 were first nucleotides in the ribozyme catalytic domain, showed no viral inhibition (Figure 4c ). At the challenge dosage of transduced with the pSLXCMV retroviral vector containing either ribozyme-II, -V, or combined ribozyme-II+V, MOI (0.22) there was no difference in viral growth between the control cells and all ribozyme-expressing expressed under the control of an internal cytomegalovirus (CMV) promoter ( Figure 3 ). The same individual cells ( Figure 4b ). Thus, the anti-HIV-1 effects of these ribozymes can be overwhelmed with a very high viral ribozymes were also constructed to be under the control of a pol III promoter (tRNA) in the DCt retroviral vector input. Of note, with CMV promoter-driven anti-RRE ribozymes, none of the tested constructs showed any pro-( Figure 3 ). Due to the inserted DNA size limitation in the pol III transcription unit (eg for efficient transcription not tection in HIV-1 challenges, with even low MOIs of 0.004 or above ( Figure 4a ). more than 80 bases (unpublished data)), the ribozyme-II+V fragment was not inserted into the DCt vector. As a control, an anti-mouse immunoglobulin gene kappa Transcription of ribozyme RNA from CMV or tRNA promoters chain (abV) ribozyme was cloned into both retroviral vectors. 21 The failure of ribozymes driven from an internal CMV promoter, but not tRNA-promoter derived ribozymes, to In order to distinguish the mechanism(s) of inhibition of HIV-1 replication, via antisense and/or ribozyme funcinhibit HIV-1 replication prompted us to investigate the transcription levels of these ribozymes in retroviral vections, the RRE ribozyme-V sequence was mutated AA to TT, in the ribozyme catalytic domain, to disrupt tors. As indicated in Figure 3 , there are at least two promoters on each of the analyzed vectors. Previously, we ribozyme function but maintain antisense arms ( Figure  1 ). This mutated ribozyme DNA fragment was also have shown that the murine leukemia virus-long terminal repeat (MLV-LTR) can maintain reasonable traninserted into the DCt vector as a control. After transduction of each of the ribozyme constructs into SupT1 cells, scriptional activity in SupT1 or CEM cells for more than 6 months. 7 Thus, all of tRNA promoters' transcriptional transduced cells were selected in 1 mg/ml of G418 for 3 weeks. Utilizing G418-resistant clones, limiting dilution orientations in the constructs were designed in the same direction as the 5′ MLV-LTR, so antisense effects of the was performed 2 days after transduction in G418 selection for 3 weeks. Then, both pooled mixed populations LTR-driven transcripts would not alter tRNA-driven transcripts. pSLXCMV and pDCT constructs ( Figure 5a ) and individual resistant clones were analyzed in HIV-1 challenge experiments. The data summarized in Figure 4 , were packaged and transduced into SupT1 cells for 2 months and the total cellular RNA was extracted for at different multiplicities of infection (MOIs) with the size of and lack of a poly-A tail on tRNA-derived transcripts may make the ribozyme RNA more efficient in ation of Rev function. 7 As such, we next combined the protein-and RNA-based intracellular strategies to attempt to improve viral inhibition and prevent possible Northern blot analysis, using a ribozyme DNA fragment as a probe (Figure 5b ). Of note, all of the promoters on escape mutations. The MluI-BglII DNA fragment, which contains the tRNA promoter-ribozyme-V and pol III terthe retroviral vectors expressed transcripts. The transcription level from the internal CMV promoter actually minal function unit, was inserted into the pSLXCMVD8SFv 3′ LTR NaeI site, with the same transcriptional showed stronger expression than the tRNA promoter in these experiments. Several repeat experiments demonorientation as the CMV promoter in this vector (see Figure 3 ). This dual-functioning retroviral vector was then strated the CMV promoter yielding better transcriptional activity, as compared to the tRNA promoter (Figure 5b) . packaged in PA317 cells and transduced into SupT1 cells and human peripheral blood mononuclear cells (PBMC) This may be explained by higher transcription activity of the CMV promoter, or CMV-derived pol II transcripts, for HIV-1 challenge experiments. The protein expression of D8SFv from this vector was confirmed using Western which carry a poly-A tail, may be more stable than transcripts from the tRNA promoter. Nevertheless, the small blotting, as indicated in Figure 6 . In the acute HIV-1 of anti-Rev SFv, anti-RRE-ribozyme, and the dualfunctioning expression vector on HIV-1 chronically infected cells, each of the packaged retroviral vectors was transduced into H9/IIIB cells. After 2 weeks of G418 selection, the mixed populations of cells were maintained in G418-free medium for 3 weeks, then HIV-1 p24 antigen production from the transduced H9/IIIB cells was quantified. As indicated in Figure 8 , anti-Rev SFv and the trans-dominant negative mutant Rev protein, RevM10, demonstrated 40-50% inhibition of viral replication, but the ribozyme alone only reduced the HIV-1 p24 antigen production level by 18-27%. When the anti-Rev and ribozyme dual retroviral vector was transduced into the H9/IIIB cells, 75-84% inhibition of viral replication inhibition was achieved ( Figure 8 ). As such, a dual protein-and RNA-based approach may be efficient for genetic therapeutics targeting chronically HIV-1-infected cells.
Discussion
A number of strategies have recently been explored to render human cells resistant to HIV-1 replication. 1,2 As a further development of intracellular immunization strategies against HIV-1 infection, suitable combinations of different anti-HIV-1 moieties, which specifically inhibit different key HIV-1 proteins or viral RNA elements, will not only be able to enhance antiviral efficiency, but also prevent possible escape mutants. 3 The viral early-gene product, Rev, which controls the expression of the structural genes of HIV-1, exerts its function through binding to an RNA element, RRE. HIV-1 RRE, located in the envelope's RNA sequence, consists of 234 nucleotides and can assume a highly complex secondary structure consisting of a central stem and five stem-loops.
2,22 By binding to RRE, specifically stem-loop II, HIV-1 Rev functions as a chaperone to transport unspliced viral RNA into the cytoplasm, for viral struc- tural protein translation and viral genome packaging.
22
As RRE functions in the productive HIV-1 life-cycle, disrupting the RRE structure using minimal RRE oligomers as a molecular decoy has been explored, as an intracelluinfection experiments, this dual-functioning vector showed improved viral inhibition, as compared with lar immunization strategy against HIV-1 replication.
23,24
In vivo binding of multimers of HIV-1 Rev protein to the D8SFv alone. In three HIV-1 challenge experiments, increased inhibition by this dual-functioning retroviral RRE during HIV-1 replication may form a protected RRE-Rev protein complex. As such, this complex may vector was observed, dependent on the challenge HIV-1 dosage (MOI). Figure 7a and b illustrates representative not be so easily targeted by ribozymes. As we have demonstrated in our anti-HIV-1 Rev SFv studies, functional experiments using SupT1 cells and human PBMC, which were challenged with HIV-1 NL4-3 and a primary HIV-1
Rev can be trapped in a cytoplasmic location by complexing with a cytoplasmic SFv protein, and this SFv isolate (SI 92006262), respectively. Although there was significant variability in independent experiments of reduces intracellular Rev half-life more than four-fold, to less than 4 h. 17, 25 Thus, the HIV-1 RRE RNA region will absolute HIV-1 p24 antigen expression, there was always a 0.5 to 1.0 log decrease in HIV-1 replication, comparing not be efficiently bound by the Rev protein in the presence of the SFv and, thus, the open structure (ie loop II the D8SFv plus the ribozyme-V with D8SFv alone.
of the RRE) may allow further targeting of the RRE RNA region by specific ribozymes. Fine mapping has shown HIV-1 replication in chronically infected cells can be inhibited with combination intracellular immunization that sequences within stem-loop II encode the primary determinants for Rev function and are the major binding strategies The concept of anti-HIV-1 gene therapy, using intracellusites for Rev. 23 Importantly, data have also demonstrated that the interaction between Rev and the RRE is absollar immunization strategies, should not only protect the cells which have not yet been infected by HIV-1, these utely required for HIV-1 replication. 26 We now describe the use of an HIV-1 RRE-specific hammerhead-like approaches should also be able to inhibit the replication of HIV-1 in chronically infected cells to reduce viral load ribozyme as an anti-HIV-1 intracellular immunization methodology, and by combination with anti-Rev SFv, in different stages of disease. To test the inhibitory effects forms an HIV-1-specific dual-blocking strategy to inhibit blotting for more than 2 months ( Figure 5 and Ref. 20) . Of note, RNA transcripts from a CMV promoter are more acute and chronic HIV-1 infection.
Figure 5 (a) Retroviral vector constructs and predicted promoter transcripts. RNA (a): transcripts from MLV-LTR promoter in pSLXCMV vector; RNA (b): transcripts from internal CMV promoter in pSLXCMV; RNA (c): transcripts from MLV-LTR promoter in pDCT-ribo-V vector; RNA (d): transcripts from tRNA promoter in pDCT-ribo-V. (b) Northern blot analysis of ribozyme RNA and GAPDH mRNA in G418-selected SupT1 mixed population cells transduced with retroviral vectors, carrying ribozymes under the control of the tRNA or internal CMV promoter. SupT1 cells were transduced with different ribozyme-carrying retroviral vectors and selected for 2 weeks. Then the cells were maintained in G418-
In the present study, we have first targeted HIV-1 RNA than 2 kb in size. Recent data have suggested that the 3′ ribozyme structure is important for both ribozyme stabusing a ribozyme-based strategy. Considering the specificity of ribozymes, the hammerhead-like structure was ility and function. 15 A large ribozyme construct may not be suitable for intracellular functioning of the moiety. chosen to target HIV-1 RNA, with each arm sequence approximately 14-20 bases. 18 For a combined strategy to Modification to a pol III-type promoter expression system may not result in a much higher expression level for interrupt the Rev-RRE interaction, our laboratories had already developed the anti-Rev SFv, and now extend ribozyme moieties, as compared to pol II promoters, but the smaller size of the ribozymes may more efficiently these on-going studies to target the RRE as an HIV-1 RNA motif. To target GUC sites, shown in Figure 1 , both access and bind the target RNA. 28 In the present studies, ribozyme-II and ribozyme-V were also cloned into a DCtribozyme-II and ribozyme-V GUC motifs were chosen, near the RRE loop regions, which have potential accessibased retroviral vector for evaluation of antiviral efficiency in transduced SupT1 cells. In this vector, bility for ribozyme cleavage.
Using the in vitro ribozyme cleavage reactions, both ribozyme-V alone demonstrated inhibition of HIV-1 replication. When the ribozymes-II and -V were combined ribozyme-II and ribozyme-V showed similar efficiency and a combination of ribozyme-II and -V could enhance in vitro for cleavage of RRE RNA, they showed an additive effect on the targeted RNA, but CMV-driven the in vitro efficiency. These moieties were cloned as single or combined ribozymes downstream of the CMV ribozymes-II+V demonstrated no improvement of antiviral function. So far in our laboratory, we have found promoter in pSLXCMV, which has been shown to be suitable for high-level protein expression. 27 There were only that data from an in vitro assay generally do not correspond to the in vivo efficiency of ribozymes (data not minimal anti-HIV-1 effects detected after the vectors were transduced into SupT1 cells, even though the CMVillustrated). Ribozyme-V, when placed in the tRNA functional casdriven ribozymes could easy be detected by Northern One of the major benefits of the dual-blocking HIV-1 strategy is to prevent possible escape mutants during long-term HIV-1 infection, which every anti-HIV-1 therapy has to approach. However, we have not yet found an escape mutation which is generated from the anti-Rev D8SFv-based method, which specifically targets the highly conserved Rev activation domain. 17 Of importance, these data demonstrate an additive modest effect of the combination of a specific RNA-and protein-based approach to anti-HIV-1 gene therapy. This effect, although modest in absolute numbers, may hold importance if in vivo HIV-1 RNA are already low, based on other therapeutics. Certainly, only in vivo phase II studies will be useful in the final analysis. Improvement of long-term expression vectors, the combination of blocking the HIV-1 life-cycle at pre-and post-integration sites, or dual strategies to inhibit HIV-1 replication targeting viral protein and RNA in host cells, clearly provide reason for cautious optimism that such approaches might succeed as molecular therapeutics for clinical HIV-1 infection.
Materials and methods

Ribozyme designs and constructions
The sequences of the targeted HIV-1 (IIIB strain) RRE region and designs of the ribozymes are illustrated in Figure 1 . As the target sites for ribozymes, two GUC sequences in the highly conserved HIV-1 RRE stem-loop II and V regions have been chosen, due to their locations near the RNA loop structures, which may be quite approachable for ribozyme cleavage and also are highly conserved regions in most HIV-1 isolates. The two ribozymes were named for RRE domains II and V, which are based on a computer-generated RRE RNA structure, utilizing the RNA-Fold program. 19 For the design of trans-acting HIV-1 ribozymes, designated ribozyme-HIV-II and ribozyme-HIV-V, respect- RNA structure. 18 For the construction of the ribozymes, protein expression was evaluated with a rabbit anti-mouse kappa chain antibody. ␤-Actin was probed with a rabbit anti-human ␤-actin antibody.
two complementary oligonucleotides were synthesized. added to the 5′ ends of the oligonucleotides used to create ribozymes-V and -II, respectively. The sequences of oligonucleotides were as follows: sense primer for sette, can reproducibly inhibit HIV-1 replication. This pol III-ribozyme unit was further inserted into ribozyme-II-1: 5′-AGGATCCTGTACCGTCAGCGTCA TTCTGATGAGTCCGTGAGGACG-3′, antisense for pSLXCMVD8SFv within the 3' MLV-LTR U3 region, to generate the dual-functioning anti-HIV-1 construct. Of ribozyme-II-2: 5′-CACGCGTGCACTATGGGCGCAGCG TTTCGTCCTCACGGACTCATC-3′, sense for ribozymenote, the 'double copy' vector is thought to enhance expression from the promoter by duplicating the tRNA V-1: 5′-CACGCGTGGAGCTGCTTGATGCCCCACTGAT GAGTCCGTGAGGACG-3′, antisense for ribozyme-V-2: cassette in target cells. 23 By targeting HIV-1 Rev with anti-Rev SFv and disrupting the RRE with ribozyme-V, 5′-CACTCGAGCATCTGTTGCAACTCACAGTTTCGTCC TCACGGACTCATC-3′. For the construction of a mutant an increased anti-HIV-1 effect can now be illustrated in both acute HIV-1 infection and most importantly chronribozyme-V as control, a two nucleotide AA to TT switch was created in the catalytic domain to disrupt ribozyme ically infected human T lymphocytes in cell culture.
Although utilizing both a combined RNA-and proteinfunction but maintain the antisense arm. This oligonucleotide, ribo-Vm2 was: 5′-CACTCGAGCATCTGTTGCAA based approach to inhibit HIV-1 is attractive for several reasons noted above, the scheme also has several com-CTCACAGTAACGTCCTCACGGACTCATC-3′. The ribozymes in DNA form were synthesized by incubating 1 plexities to overcome, including promoter types and locations of therapeutic moieties within vector constructs.
g of two oligonucleotides to form a hemiduplex. Then polymerase chain reaction (PCR) amplifications were per-USA) to generate a plasmid, pGRRE, which contains two GUC sites as the targets for the HIV-1 RRE ribozyme-II formed in a 100 l volume containing: 10 mm Tris-HCl (pH 8.3), 50 mm KCl, 2.5 mm MgCl 2 , 200 m of each and V. The proper construction of the ribozymes and RRE RNA were confirmed by DNA sequencing, using the dNTP and 5 Units of Taq polymerase (Perkin-Elmer, Foster City, CA, USA). The cycle conditions were as follows:
PRISM Ready Reaction DyeDeoxy Terminator Cycle Sequencing Methodology (ABI, Foster City, CA, USA). 94°C for 1.5 min, 50°C for 1.5 min and 72°C for 2 min for 10 cycles. Then, PCR products were directly cloned into the pT7Blue-T vector (Novagen, Madison, WI, USA) to
In vitro transcription and ribozyme cleavage reactions pT7-ribo-II and pT7-ribo-V, containing the ribozyme generate plasmids pT7ribo-II and pT7ribo-V. For cloning the RRE RNA, to generate the substrate RNA for sequences, were digested with SmaI to linearize the plasmids, then transcribed with bacteriophage T7 RNA polyribozyme-II and ribozyme-V in in vitro cleavage reactions, two oligonucleotides were synthesized (sense merase in the presence of ␥-32 P UTP to generate ribozymes-II and V of 117 and 127 bases, respectively. primer, RREp-1: 5′-TTCTTGGAGCAGCAGGGAG-3′; antisense primer, RREp-2: 5′-CTAGGATTCTTGCTT pGRRE, containing the RRE RNA sequence, was linearized with SalI and transcribed with T7 RNA poly-GGA-3′), and subjected to PCR, using the HIV-1 HXB2 plasmid (R7) as a template. PCR amplification for 35 merase in the presence of ␥-32 P UTP to generate a substrate RRE RNA of 292 bases. The ribozyme and substrate cycles consisted of 94°C for 1.5 min, 50°C for 1.5 min, and 72°C for 2 min. The 226 base-pair PCR product was then RRE RNA were incubated in a 10 l reaction volume containing: 50 mm Tris-HCl (pH 7.5), 1 mm EDTA and 10 cloned into the pGEM-T vector (Promega, Madison, WI,
541
For subcloning of the ribozymes, ribozyme-II was excised from pT7ribo-II with BamHI, and cloned into the BglII site downstream of the internal CMV promoter in the pSLXCMV vector, to generate pSLXCMVribo-II (Figure 3 ). Ribozyme-V was excised from pT7ribo-V with MluI and XhoI, and cloned into the MluI-XhoI sites in the pSLXCMV vector to create pSLXCMVribo-V. For cloning both ribozyme fragments downstream of the CMV promoter, firstly, the EcoRI-XbaI fragment from pT7ribo-II was inserted into pSP72 vector's (Boehringer Mannheim) EcoRI-XbaI sites to generate pSP-RRE-II, then the XbaISmaI fragment which contains ribozyme-V from pT7 ribo-V was inserted into pSP-RRE-II's XbaI-PvuII sites to produce pSP72-RRE-II+V. To place the double ribozyme downstream of the CMV promoter, the BglII-XhoI fragment was inserted into pSLXCMV's BglII-XhoI sites (Figure 3) .
Retroviral vector pDCt2T ( Figure 3 ) was used to insert ribozyme-V into the tRNA promoter cassette; tRNA/Met (D3-2) gene with an RNA polymerase (pol) III termination signal. 13, 29 This construct is called a 'double copy' vector because the tRNA promoter is inserted in the U3 region of the 3′-long terminal repeat (LTR). When the recombinant virus is transduced into a target cell-line, the U3 region in the 3′-LTR is used as a primer for synthesis of the 5′-LTR. Then, this tRNA promoter cassette is duplicated in the 5′-LTR.
Briefly, for ribozyme subcloning, the 74 bp fragment of ribozyme-V was removed using digestions with SacII and BamHI from the pSP72-ribozyme-V vector and was then inserted into SacII-BamHI sites of pDCt2T, to generate pDCT-RRE-ribozyme-V. As a control for the RRE ribozyme constructs, the abV ribozyme developed in our laboratory, 21 which specifically targets the mouse 5′-GAGATCTATTCTTTAGCTCCTGA-3′ and the 372 bp Rev M10 DNA fragment was cloned into pT7Blue(R) for DNA sequencing. Then, the EcoRI-BglII M10 fragment mm MgCl 2 . These RNAs were heated to 95°C for 2 min and cooled on ice. The reactions were performed at 37°C was inserted into pLSXN via EcoRI-BamHI sites to generate the M10 expression plasmid, pLSXN-M10. for 20 min, then the reactions were stopped by the addition of an equal volume of 95% formamide, 20 mm For construction of the dual-functioning retroviral construct, pSLXCMV-D8SFv-tRNA-V, which carries both a EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol, and heated to 65°C for 5 min. The reaction proribozyme and the anti-Rev D8SFv, the tRNA promoterribozyme-V-terminal function fragment was recovered ducts were separated on a 6% polyacrylamide-7 m urea gel in TBE buffer. The labeled RNAs were then visualized from pDCT-RRE-ribozyme-V with BglII and MluI digestions, and blunted via the Klenow reaction. The fragment by autoradiography.
was then inserted into the NheI site of the MLV 3′ LTR by partial digestion of pSLXCMV-D8SFv (see Figure 3) . 7 
Retroviral vectors
Three murine leukemia virus (MLV) vectors, containing the neomycin-resistance (neo) gene as a selectable marker, Cell cultures and transfections The SupT1 and CEM cells are CD4 + human T lymphowere utilized for the expression of anti-HIV-1 moieties in target cells. Retroviral vector pLXSN, and pSLXCMV cytic cell lines, susceptible to HIV-1 infection, 7 which are grown in RPMI-1640 medium supplemented with 10% which contains an internal human immediate-early cytomegalovirus (CMV) promoter, were used. 27 For fetal calf serum (FCS). H9/IIIB is a stable T cell line which has been chronically infected with the HIV-1 IIIB strain.
30
expression of anti-HIV-1 Rev SFvD8 and chloramphenicol acetyl transferase (CAT) as controls, retroviral The retroviral packaging cell-line, PA317, 27, 31 was grown in DMEM supplemented with 10% FCS. All the cells were vectors encoding these moieties have been described previously. 7 grown at 37°C in a humidified incubator with 5% CO 2 .
For production of helper-free, recombinant MLV-based duced SupT1 cells was extracted by a modification of the method of Chomczynski and Sacchi. 34 Expression of retroviral vectors, subconfluent PA317 cells were transfected with 10 g of retroviral expression plasmids, using CMV or tRNA promoter-driven ribozymes was detected by Northern blot hybridization analyses, as described a standard calcium-phosphate transfection method (Promega), according to the manufacturer's instructions.
previously, 20 employing a ribozyme cDNA probe and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) After 48 h, medium containing recombinant retrovirus particles was collected and titers of the retroviral shuttle cDNA as a control. Samples of total RNA (20 g) were denatured in buffer containing 0.5 mg/l glyoxal, 50% vectors were determined, as described previously. 7 Peripheral blood mononuclear cells (PBMC) were obtained dimethyl sulfoxide, 10 mm phosphate, and then electrophoresed in 1% agarose gels, transferred to Geneby Ficoll-Hypaque separation of phlebotomized blood from HIV-1-seronegative individuals.
Screen filters (New England Nuclear, Boston, MA, USA), and baked for 2 h at 80°C. The filters were prehybridized and were subsequently hybridized under stringent conTransduction of T lymphocytic cells and viruses Each target cell type was infected with recombinant retroditions with the ribozyme or GAPDH DNA fragments labeled with ␣-32 P dCTP, using a primer extension methviral vectors, overnight, in the presence of 8 g/ml polybrene. On day 3 after transduction, the cells were odology (Amersham, Arlington Heights, IL, USA). After hybridization, the filters were washed and the signals selected with 1 mg/ml of G418 (Gibco-BRL, Gaithersburg, MD, USA) for 3 weeks. G418-resistant clones were were visualized by autoradiography. generated by limiting dilution or pooled. Both individual Protein extraction and Western blot analysis clones and mixed pooled cell populations were subjected Cells transduced with retroviral vector pCMVto further functional analyses.
D8SFv/tRNA-V, or nontransduced cells, were lysed as For human PBMC, after 3 days of phytodescribed previously. 35 Proteins were subjected to hemagglutinin/interleukin II stimulation (PHA, 5 g/ml, electrophoresis in 10% sodium dodecyl sulfate polyacrylSigma, St Louis, MO, USA; IL-2 100 U/ml, United Cross amide gels and subsequently transferred to a Poly Screen Int'l Biotech, Beijing, PRC), 1 × 10 6 /ml cells were cultured (PVDF) membrane (Dupont). After the membrane was with 10 ml of transfected PA317 supernatant, for 3 days, blocked with 5% non-fat dry milk, the specific protein with daily replacement of fresh packaging cell-line superexpression was detected with rabbit polyclonal antinatant. The transduced PBMC, cultured only in IL-2 (50 mouse kappa chain (Sigma) for D8SFv. As a control, rab-U/ml), were challenged with HIV-1.
bit anti-human ␤-actin antibodies were used. The Dupont For chronically infected H9/IIIB cells, transfected cells Western Blot Chemiluminescence methodology was utilwere first selected in G418 for 2 weeks and maintained ized, with the manufacturer's suggested protocol in the G418-free culture medium for 2 more weeks. Then, (Dupont). HIV-1 replication was assayed by measuring HIV-1 p24 antigen level in the supernatants, with standard cell cultures at 0.5-1 × 10 6 cells per ml, and subcultured every 3
